{{Rsnum
|rsid=3877899
|Gene=SEPP1
|Chromosome=5
|position=42801166
|Orientation=plus
|GMAF=0.1919
|Gene_s=CCDC152,SEPP1
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 6.2 | 39.8 | 54.0
| HCB | 0.0 | 1.5 | 98.5
| JPT | 0.0 | 0.9 | 99.1
| YRI | 6.1 | 36.1 | 57.8
| ASW | 7.0 | 45.6 | 47.4
| CHB | 0.0 | 1.5 | 98.5
| CHD | 0.0 | 0.0 | 0.0
| GIH | 0.0 | 17.8 | 82.2
| LWK | 5.5 | 56.9 | 37.6
| MEX | 1.8 | 19.3 | 78.9
| MKK | 7.7 | 34.6 | 57.7
| TSI | 2.0 | 33.3 | 64.7
| HapMapRevision=28
}}{{PMID Auto
|PMID=19453253
|Title=Relative abundance of selenoprotein P isoforms in human plasma depends on genotype, se intake, and cancer status
}}

{{PMID|19074884|OA=1
}} Interaction between single nucleotide polymorphisms in selenoprotein P and mitochondrial superoxide dismutase determines prostate cancer risk.

{{PMID|20852007}} Effects of selenium status and polymorphisms in selenoprotein genes on prostate cancer risk in a prospective study of European men.

{{PMID|22139612|OA=1
}} Serum selenium and single-nucleotide polymorphisms in genes for selenoproteins: relationship to markers of oxidative stress in men from Auckland, New Zealand.

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | FTDNA}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}